# US 2024/0189419 A1 · Method for the prophylaxis or treatment of coronavirus infection using an immunomodulator and vaccine compositions comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189419 A1
- Document ID: US20240189419A1
- Status: Published application
- Kind: A1
- Application number: 18/583,389
- Filed: 2024-02-21
- Published: 2024-06-13
- Earliest claimed: 2020-05-08
- Assignees: Advagene Biopharma Co., Ltd.
- Applicants: Advagene Biopharma Co., Ltd.
- Inventors: YU-SHEN HSU; SSU-WEI KANG; MING-I CHANG
- Web page: https://patentgrep.com/patent/US20240189419A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/55544: {Bacterial toxins}
- A61P 31/14: for RNA viruses
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides a method for the treatment or prophylaxis of coronavirus infection, comprising administering a therapeutically effective amount of an immunomodulator to a subject in need thereof or at risk of coronavirus infection. A vaccine composition comprising a pharmaceutically effective amount of an immunomodulator is also provided.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method for inducing IFNα production in epithelial cells of a subject, comprising administering the epithelial cells of the subject a therapeutically effective amount of an immunomodulator.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the immunomodulator is a detoxified Escherichia coli labile toxin (LT), a Toll-Like Receptor (TLR) agonist or antagonist, Vaxfectin, or a pattern recognition receptor (PRR) agonist or antagonist.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the LT is LTh(αK).

### Claim 17 (depends on 14)

The method according to claim 14, wherein the epithelial cells are respiratory tract mucosal epithelial cells.
